Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

Powles, T.; Burotto, M.; Escudier, B.; Apolo, A. B.; Bourlon, M. T.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C. H.; Richardet, M.; Gurney, H.; Kessler, E. R.; Tomita, Y.; Bedke, J.; George, S.; Scheffold, C.; Wang, P.; Fedorov, V.; Motzer, R. J.; Choueiri, T. K.

Publication services
→
Universitätsbibliographie
→
4 Medizinische Fakultät
→
View Item

« back

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

Author:

Powles, T.; Burotto, M.; Escudier, B.; Apolo, A. B.; Bourlon, M. T.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C. H.; Richardet, M.; Gurney, H.; Kessler, E. R.; Tomita, Y.; Bedke, J.; George, S.; Scheffold, C.; Wang, P.; Fedorov, V.; Motzer, R. J.; Choueiri, T. K.

Tübinger Autor(en):

Bedke, Jens

Published in:

Esmo Open (2024), Bd. 9 (5), Article 102994

Verlagsangabe:

Amsterdam : Elsevier

Language:

English

Full text:

http://dx.doi.org/10.1016/j.esmoop.2024.102994

ISSN:

2059-7029